文献速递慢性肾脏病肾血管病与高血压

射血分数降低心力衰竭患者RAAS抑制后肾功能结局趋势

Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
PubMed 文献 · Am J Kidney Dis · 2019-07-11

该研究为SOLVD试验事后分析,纳入有症状(n=2423)和无症状(n=4094)心力衰竭患者,比较依那普利与安慰剂对eGFR斜率及肾脏终点的影响。结果显示依那普利组早期eGFR下降,但3年随访期间eGFR斜率无统计学差异,早期肾脏终点风险增加但1年后无显著关联。

要点

  • 依那普利治疗早期eGFR下降,但长期斜率与安慰剂无显著差异。
  • 治疗试验中依那普利组前6周肾脏终点风险增加,1年后风险无显著升高。
  • 预防试验呈现类似但较弱的早期风险模式。

核心结论

  • HFrEF患者肾功能下降缓慢,依那普利仅早期增加肾脏替代终点风险,长期eGFR斜率和风险与安慰剂无差异。

研究设计与样本

  • SOLVD试验事后分析,纳入有症状(治疗试验,n=2423)和无症状(预防试验,n=4094)患者,比较依那普利与安慰剂。

主要发现

  • 治疗试验基线平均eGFR为69.5±19.8 mL/min/1.73m2,预防试验为76.2±18.6 mL/min/1.73m2。
  • 中位3年随访期间,治疗试验eGFR斜率依那普利组-0.84 vs 安慰剂组-1.36 mL/min/1.73m2/年(P=0.08)。
  • 预防试验eGFR斜率依那普利组-1.27 vs 安慰剂组-1.36 mL/min/1.73m2/年(P=0.7)。
  • 治疗试验前6周,依那普利组肌酐升高≥0.3mg/dL风险HR 1.48(95%CI 1.10-1.99),eGFR下降>40%风险HR 2.60(95%CI 1.30-5.21),eGFR<30风险HR 4.71(95%CI 1.78-12.50)。
  • 治疗试验1年后依那普利与肾脏终点风险增加无显著关联;预防试验仅早期风险存在。

临床怎么用

  • HFrEF患者使用依那普利时,应关注早期eGFR下降和肌酐升高,但长期肾功能下降速率与安慰剂相似。

局限性

  • 肌酐结果未设盲,ACE抑制剂/安慰剂剂量可能受肌酐水平影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Angiotensin-converting enzyme (ACE) inhibitors are beneficial in heart failure with reduced ejection fraction (HFrEF). We sought to describe longitudinal trends in estimated glomerular filtration rate (eGFR) in HFrEF and how ACE-inhibitor therapy influences these changes. STUDY DESIGN: Post hoc analysis of trial data. SETTINGS & PARTICIPANTS: Symptomatic (Treatment Trial, n=2,423) and asymptomatic (Prevention Trial, n=4,094) patients from the Studies of Left Ventricular Dysfunction (SOLVD). EXPOSURE: Enalapril versus placebo. OUTCOMES: Early and long-term eGFR slope (ie, within and after the first 6 weeks) and 4 kidney end points: (1) serum creatinine level increase by≥0.3mg/dL, (2)>30% eGFR decline, (3)>40% eGFR decline, and (4) incident eGFR<30mL/min/1.73m2. ANALYTICAL APPROACH: Shared parameter models, multivariable Cox regression models. RESULTS: Baseline mean eGFR was lower in the Treatment Trial than in the Prevention Trial, 69.5±19.8 (SD) versus 76.2±18.6mL/min/1.73m2. Following randomization, an early eGFR decline occurred in the enalapril group; however, slopes during the median 3-year follow-up were not statistically different by randomization arm in either the Treatment Trial (-0.84 in enalapril vs-1.36mL/min/1.73m2 per year in placebo; P=0.08) or Prevention Trial (-1.27 in enalapril vs-1.36mL/min/1.73m2 per year in placebo; P=0.7). Random assignment to enalapril treatment increased the risk for all 4 outcomes in the Treatment Trial in the first 6-week period (HRs were 1.48 [95% CI, 1.10-1.99] for creatinine increase by≥0.3mg/dL; 1.38 [95% CI, 0.98-1.94] for eGFR decline> 30%; 2.60 [95% CI, 1.30-5.21] for eGFR decline> 40%; and 4.71 [95% CI, 1.78-12.50] for eGFR<30mL/min/1.73m2), but after the first year was not significantly associated with increased risk. A similar albeit less pronounced pattern was observed in the Prevention Trial, with risks present only in the early period. LIMITATIONS: Creatinine results were not blinded, making it possible that ACE-inhibitor/placebo dosing was influenced by creatinine level. CONCLUSION: Kidney function decline is slow in HFrEF. Although random assignment to enalapril treatment results in a statistically increased risk for kidney surrogates, the risk is limited to the early phase and late eGFR slopes and risks are not different by randomly assigned group.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. McCallum W, Tighiouart H, Ku E, et al. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction. Am J Kidney Dis. 2019. PMID: 31303349. doi:10.1053/j.ajkd.2019.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。